Never smoking, CRP ≥ 1 mg/dL, liver metastasis, pleural effusion, and steroid use were predictive of shorter PFS in patients with NSCLC treated with nivolumab with good PS, whereas ALI ≥ 18 was predictive of longer PFS in patients with NSCLC treated with nivolumab with poor PS. The gene discussed is CRP; the disease is Pleural effusion.